Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Innovation Pharmaceuticals Inc (EM) IPIX

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.


EXPM:IPIX - Post by User

Post by Brito1on Feb 07, 2020 2:21pm
277 Views
Post# 30659598

Current state of affairs

Current state of affairs
Nefarious criminal activity against this company is a given. Is there unlimited air shares available to the naked shorters, who knows. One thing we can take solace in is that the company progresses forward despite inept attempts by this group to initiate a mass sell off. Shares are held tightly by battle hardened longs and shorts are caught between a rock and a hard place. To garner the quantity of shares to cover would require allowing the stock to run past the $2 mark. As the noose tightens the criminals have no game and are soon to realize that they are dead shorts walking.
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities